Geode Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $73.6M | Buy |
2,972,402
+72,065
| +2% | +$1.72M | ﹤0.01% | 1271 |
|
|
2025
Q4 | $67.7M | Buy |
2,900,337
+10,017
| +0.3% | +$223K | ﹤0.01% | 1314 |
|
|
2025
Q3 | $56.9M | Buy |
2,890,320
+23,637
| +0.8% | +$486K | ﹤0.01% | 1392 |
|
|
2025
Q2 | $62.2M | Buy |
2,866,683
+101,127
| +4% | +$2.39M | ﹤0.01% | 1313 |
|
|
2025
Q1 | $67.1M | Buy |
2,765,556
+100,084
| +4% | +$2.25M | 0.01% | 1202 |
|
|
2024
Q4 | $55.6M | Buy |
2,665,472
+1,048
| +0% | +$22.5K | ﹤0.01% | 1363 |
|
|
2024
Q3 | $53M | Sell |
2,664,424
-34,189
| -1% | -$634K | ﹤0.01% | 1391 |
|
|
2024
Q2 | $41.8M | Buy |
2,698,613
+190,461
| +8% | +$2.97M | ﹤0.01% | 1471 |
|
|
2024
Q1 | $40M | Buy |
2,508,152
+307,927
| +14% | +$4.64M | ﹤0.01% | 1509 |
|
|
2023
Q4 | $37M | Buy |
2,200,225
+113,858
| +5% | +$1.56M | ﹤0.01% | 1524 |
|
|
2023
Q3 | $24.4M | Buy |
2,086,367
+159,952
| +8% | +$2.14M | ﹤0.01% | 1699 |
|
|
2023
Q2 | $25.9M | Buy |
1,926,415
+72,193
| +4% | +$1.04M | ﹤0.01% | 1682 |
|
|
2023
Q1 | $30.7M | Buy |
1,854,222
+90,832
| +5% | +$1.5M | ﹤0.01% | 1517 |
|
|
2022
Q4 | $32.8M | Buy |
1,763,390
+76,269
| +5% | +$1.17M | ﹤0.01% | 1441 |
|
|
2022
Q3 | $21.6M | Sell |
1,687,121
-4,671
| -0.3% | -$55.4K | ﹤0.01% | 1669 |
|
|
2022
Q2 | $11.9M | Sell |
1,691,792
-62,178
| -4% | -$456K | ﹤0.01% | 2135 |
|
|
2022
Q1 | $14.5M | Buy |
1,753,970
+23,657
| +1% | +$167K | ﹤0.01% | 2099 |
|
|
2021
Q4 | $11.7M | Sell |
1,730,313
-166,663
| -9% | -$1.1M | ﹤0.01% | 2343 |
|
|
2021
Q3 | $10.1M | Buy |
1,896,976
+32,343
| +2% | +$177K | ﹤0.01% | 2453 |
|
|
2021
Q2 | $10.7M | Buy |
1,864,633
+97,768
| +6% | +$505K | ﹤0.01% | 2410 |
|
|
2021
Q1 | $8.14M | Buy |
1,766,865
+164,171
| +10% | +$652K | ﹤0.01% | 2499 |
|
|
2020
Q4 | $5.35M | Buy |
1,602,694
+54,666
| +4% | +$184K | ﹤0.01% | 2568 |
|
|
2020
Q3 | $4.6M | Sell |
1,548,028
-26,464
| -2% | -$103K | ﹤0.01% | 2437 |
|
|
2020
Q2 | $7.27M | Buy |
1,574,492
+33,135
| +2% | +$149K | ﹤0.01% | 2115 |
|
|
2020
Q1 | $5.93M | Buy |
1,541,357
+37,036
| +2% | +$152K | ﹤0.01% | 2041 |
|
|
2019
Q4 | $5.64M | Sell |
1,504,321
-19,083
| -1% | -$89.2K | ﹤0.01% | 2380 |
|
|
2019
Q3 | $8.09M | Buy |
1,523,404
+119,613
| +9% | +$637K | ﹤0.01% | 2073 |
|
|
2019
Q2 | $5.39M | Buy |
1,403,791
+257,369
| +22% | +$1.11M | ﹤0.01% | 2332 |
|
|
2019
Q1 | $5.85M | Buy |
1,146,422
+82,654
| +8% | +$243K | ﹤0.01% | 2238 |
|
|
2018
Q4 | $2.04M | Buy |
1,063,768
+101,584
| +11% | +$291K | ﹤0.01% | 2761 |
|
|
2018
Q3 | $3.64M | Buy |
962,184
+1,616
| +0.2% | +$5.06K | ﹤0.01% | 2569 |
|
|
2018
Q2 | $3M | Buy |
960,568
+104,720
| +12% | +$318K | ﹤0.01% | 2614 |
|
|
2018
Q1 | $2.04M | Buy |
855,848
+109,837
| +15% | +$365K | ﹤0.01% | 2745 |
|
|
2017
Q4 | $2.92M | Buy |
746,011
+118,799
| +19% | +$392K | ﹤0.01% | 2537 |
|
|
2017
Q3 | $1.58M | Buy |
627,212
+13,363
| +2% | +$36.7K | ﹤0.01% | 2874 |
|
|
2017
Q2 | $1.69M | Buy |
613,849
+151,172
| +33% | +$316K | ﹤0.01% | 2825 |
|
|
2017
Q1 | $902K | Buy |
462,677
+1,446
| +0.3% | +$1.84K | ﹤0.01% | 3066 |
|
|
2016
Q4 | $484K | Buy |
461,231
+964
| +0.2% | +$1.1K | ﹤0.01% | 3276 |
|
|
2016
Q3 | $501K | Buy |
460,267
+241
| +0.1% | +$217 | ﹤0.01% | 3246 |
|
|
2016
Q2 | $326K | Sell |
460,026
-19,961
| -4% | -$16.1K | ﹤0.01% | 3396 |
|
|
2016
Q1 | $561 | Buy |
479,987
+4,314
| +0.9% | +$6.69K | ﹤0.01% | 3163 |
|
|
2015
Q4 | $1.17M | Buy |
475,673
+5,601
| +1% | +$16K | ﹤0.01% | 2821 |
|
|
2015
Q3 | $1.41M | Buy |
470,072
+62,085
| +15% | +$268K | ﹤0.01% | 2666 |
|
|
2015
Q2 | $1.68M | Buy |
407,987
+55,139
| +16% | +$220K | ﹤0.01% | 2607 |
|
|
2015
Q1 | $1.53M | Buy |
352,848
+87,104
| +33% | +$314K | ﹤0.01% | 2607 |
|
|
2014
Q4 | $789K | Sell |
265,744
-16,590
| -6% | -$45.5K | ﹤0.01% | 2973 |
|
|
2014
Q3 | $937K | Sell |
282,334
-14,926
| -5% | -$39K | ﹤0.01% | 2812 |
|
|
2014
Q2 | $751K | Buy |
297,260
+123,472
| +71% | +$264K | ﹤0.01% | 2971 |
|
|
2014
Q1 | $392K | Buy |
173,788
+8,370
| +5% | +$17.5K | ﹤0.01% | 3250 |
|
|
2013
Q4 | $322K | Hold |
165,418
| – | – | ﹤0.01% | 3258 |
|
|
2013
Q3 | $505K | Hold |
165,418
| – | – | ﹤0.01% | 2942 |
|
|
2013
Q2 | $147K | Buy |
+165,418
| New | +$132K | ﹤0.01% | 3331 |
|
Other funds holding CPRX
VCM
DM
VPM
Geode Capital Management's CPRX Position: Q1 2026 in Review
Geode Capital Management increased its Catalyst Pharmaceutical (CPRX) stake by 2.5% in Q1 2026, buying an estimated $1.72M and bringing the position to 2,972,402 shares worth $73.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1271.
Geode Capital Management first reported a position in CPRX in Q2 2013 and has held it in 52 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Geode Capital Management held 2,972,402 shares of Catalyst Pharmaceutical worth $73.6M as of Q1 2026.
- Geode Capital Management bought 72,065 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.72M.
- Catalyst Pharmaceutical made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1271 holding.
- Geode Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2013 and has held it in 52 quarters since.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.